Dr. David Gilham

Executive Scientific Advisor, Ex-Celyad

Dr. David Gilham spent almost six years at Celyad Oncology, serving first as VP R&D and then Chief Scientific Officer, developing CAR-T cell therapies against cancer. Prior to joining Celyad Oncology, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre. There his research focused on engineering T cells for cancer therapy and developing preclinical studies to support translation into Phase I/II clinical trials with Professor Robert Hawkins.